GlaxoSmithKline plc's (GSK) "Hold" Rating Reaffirmed at Deutsche Bank AG

Advisory Services Network LLC now owns 4,047 shares of the pharmaceutical company's stock valued at $175,000 after buying an additional 788 shares during the last quarter. Advisor Group Inc.'s holdings in GlaxoSmithKline PLC were worth $4,109,000 at the end of the most recent quarter.

GlaxoSmithKline plc (LON:GSK) last released its earnings results on Wednesday, October 25th. Risk Paradigm Group, LLC owns 1,200 shares valued at $48,720,000. Carroll Financial Associates Inc. increased its holdings in shares of GlaxoSmithKline PLC by 0.4% in the 2nd quarter. FTB Advisors Inc. now owns 3,735 shares of the pharmaceutical company's stock valued at $146,000 after buying an additional 539 shares during the last quarter. The company now has a P/E ratio of 27.99 and the market cap is 84.71B. The fund owned 27,930 shares of the pharmaceutical company's stock after buying an additional 2,310 shares during the period.

WARNING: "GlaxoSmithKline plc's (GSK) "Hold" Rating Reaffirmed at Deutsche Bank AG" was first reported by TrueBlueTribune and is the sole property of of TrueBlueTribune. Grimes & Company Inc. now owns 5,367 shares of the pharmaceutical company's stock worth $232,000 after buying an additional 234 shares in the last quarter. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA increased its holdings in shares of GlaxoSmithKline PLC by 1.9% in the 2nd quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 3,374 shares of the pharmaceutical company's stock valued at $137,000 after acquiring an additional 64 shares during the period. Hedge funds and other institutional investors own 8.48% of the company's stock.

Shares of GlaxoSmithKline PLC (NYSE:GSK) traded down $0.11 during trading on Tuesday, hitting $34.98. The stock was acquired at an average price of GBX 1,527 ($20.08) per share, with a total value of £16,430.52 ($21,610.57).

GlaxoSmithKline plc (NYSE:GSK) gross margin percentage stands at 69.3% while its operating margin for the past trailing twelve month is 13.9 percent and its overall profit margin (ttm) is 7.7 Percent. The company has a debt-to-equity ratio of 2.96, a quick ratio of 0.44 and a current ratio of 0.64. The firm has a market cap of $86,814.73, a PE ratio of 12.52, a P/E/G ratio of 1.96 and a beta of 1.00.

The company also recently declared a quarterly dividend, which will be paid on Thursday, January 11th. Stockholders of record on Friday, November 10th will be issued a dividend of $0.5037 per share. The ex-dividend date was Wednesday, November 2nd. This represents a $2.01 dividend on an annualized basis and a dividend yield of 5.76%. Trading volume for GlaxoSmithKline plc was 5.18 Million in its previous trading session.

The Leverage Ratio of GlaxoSmithKline plc (LSE:GSK) is 0.32379.

A number of brokerages have recently issued reports on GSK. Morgan Stanley set a GBX 1,450 ($19.07) price objective on shares of GlaxoSmithKline plc and gave the company a sell rating in a report on Monday, November 6th. Finally, J P Morgan Chase & Co restated a "neutral" rating on shares of GlaxoSmithKline PLC in a research report on Tuesday, October 24th. BidaskClub downgraded GlaxoSmithKline PLC from a "sell" rating to a "strong sell" rating in a research note on Monday, July 24th. In the latest earnings report the EPS was $1.25 with 4.92B shares now outstanding.

A number of other analysts have also weighed in on the stock. GlaxoSmithKline PLC now has a consensus rating of "Hold" and a consensus price target of $44.33.

In other news, major shareholder Plc Glaxosmithkline purchased 428,571 shares of the business's stock in a transaction dated Monday, November 6th. The stock was bought at an average price of $14.00 per share, with a total value of $5,999,994.00. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 10.00% of the company's stock. If you are reading this news story on another domain, it was copied illegally and republished in violation of USA & global copyright and trademark legislation. The legal version of this news story can be viewed at https://weekherald.com/2017/11/14/advisor-group-inc-has-4-11-million-stake-in-glaxosmithkline-plc-gsk.html.

GlaxoSmithKline is one of the world's leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare.